Released May 14, 2025, before the open
10-Q filed May 14, 2025, 44 days after period end · 0001628280-25-025312
Q1 2025 · 10-Q
Revenue$5.95M$5.95M +17.9% vs Q1 2024+108.4% vs Q4 2024
Net Income-$18.83M-$18.83M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.30-$0.30 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$22,913,000N/M
Operating Cash Flow-$23,968,000N/M
Free Cash Flowderived-$23,996,000N/M
Margins · derived
Operating margin-385.0%+173.3 pt vs Q1 2024
Net margin-316.4%+178.9 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $5.95M | $5.05M | $5.31M | $3.92M |
| Net Income | -$18.83M | -$25.02M | -$30.49M | -$26.91M |
| EPS Diluted | -$0.30 | -$0.59 | -$0.73 | -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR